Brought to you by 
Roche, Trimeris in $88mm HIV drug development pact
26 May 2011
Executive Summary
Roche and anti-infective therapeutics company Trimeris will together develop Trimeris's anti-HIV fusion inhibitors, T-20 and T-1249. Roche gets US and Canadian co-promotion rights, and exclusive rights in the rest of the world. In exchange, it pays (uf)$10mm in cash up front and granted to Trimeris a warrant to buy 362k shares of common stock at $20.72 each. Trimeris also gets up to $78mm more in developmental, regulatory, and commercial milestones.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche, Trimeris in $88mm HIV drug development pact
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice